Innoviva, Inc. (NASDAQ:INVA) Shares Acquired by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. lifted its position in Innoviva, Inc. (NASDAQ:INVA - Free Report) by 44.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 136,722 shares of the biotechnology company's stock after purchasing an additional 41,827 shares during the quarter. Harbor Capital Advisors Inc. owned about 0.22% of Innoviva worth $2,640,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Jennison Associates LLC increased its stake in Innoviva by 83.6% during the first quarter. Jennison Associates LLC now owns 77,492 shares of the biotechnology company's stock worth $1,181,000 after acquiring an additional 35,294 shares during the last quarter. Texas Permanent School Fund Corp raised its stake in shares of Innoviva by 1.4% in the 1st quarter. Texas Permanent School Fund Corp now owns 49,358 shares of the biotechnology company's stock valued at $752,000 after acquiring an additional 662 shares during the period. Empowered Funds LLC boosted its position in shares of Innoviva by 8.2% during the 1st quarter. Empowered Funds LLC now owns 249,826 shares of the biotechnology company's stock worth $3,807,000 after purchasing an additional 18,890 shares during the period. SG Americas Securities LLC acquired a new stake in Innoviva in the 1st quarter valued at approximately $138,000. Finally, QRG Capital Management Inc. raised its position in Innoviva by 9.5% in the first quarter. QRG Capital Management Inc. now owns 63,498 shares of the biotechnology company's stock valued at $968,000 after purchasing an additional 5,484 shares during the period. 99.12% of the stock is currently owned by institutional investors and hedge funds.

Innoviva Stock Up 0.4 %

INVA traded up $0.07 on Tuesday, hitting $19.43. 335,759 shares of the company were exchanged, compared to its average volume of 565,505. The firm has a 50-day moving average price of $19.56 and a two-hundred day moving average price of $17.73. The company has a current ratio of 12.70, a quick ratio of 11.40 and a debt-to-equity ratio of 0.67. Innoviva, Inc. has a twelve month low of $13.31 and a twelve month high of $20.37. The company has a market cap of $1.22 billion, a price-to-earnings ratio of 11.78 and a beta of 0.57.

Wall Street Analyst Weigh In

INVA has been the topic of several research analyst reports. Cantor Fitzgerald reiterated an "overweight" rating on shares of Innoviva in a report on Tuesday, July 30th. StockNews.com lowered shares of Innoviva from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, August 6th.

About Innoviva

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.